• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Aviir

edit

Aviir is a venture-funded biotechnology company developing cutting-edge, convenient diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology draws on years of research at Stanford University, and combines the scientific founders’ deep understanding of disease marker proteins and advanced biostatistics. Aviir is pursuing an aggressive commercialization strategy and initial products are expected to reach the market within 24 months. The Aviir team includes the founding scientists and highly experienced management.

Milestones

edit

• 
  Aviir received $10M in Series E funding. (12/20/11)
  Posted 12/20/11 at 5:25am via onbiovc.com
• 
  Aviir received $4.2M in Debt funding. (1/19/10)
  Posted 1/20/10 at 10:04pm via venturebeat.com
• 
  Aviir received $1M in Debt funding. (10/1/09)
  Posted 11/8/09 at 8:12pm via venturebeat.com
• 
  Aviir received $11.3M in Series B funding. (10/3/07)
  Posted 7/15/09 at 8:44am via venturebeat.com

Videos

Screenshots

edit

Above: Aviir
Uploaded: 7/15/09

Sources

1. Heart-diagnostic maker Aviir raises $11.3M (venturebeat.com) [edit]
2. Aviir pumps up with $1M for heart diagnostics (deals.venturebeat.com) [edit]
3. Aviir diagnoses heart conditions with new $4.2M (deals.venturebeat.com) [edit]
4. Aviir, Inc.: Series E $10M (onbiovc.com) [edit]